Monika Dmitrzak-Weglarz

2 papers in the library · publishing 2022-2026

Papers

Sort Most recent Most cited

Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders.

CNS Spectrums September 28, 2026 Magda Malewska-Kasprzak, Filip Rybakowski, Monika Dmitrzak-Weglarz

Intravenous ketamine is a rapid-acting intervention for treatment-resistant depression (TRD) in adults with major depressive disorder and bipolar disorder (BD). While efficacy is established, a comprehensive integration of clinical, neurophysiological, biomarker, metabolic, and cognitive predictors remains lacking, limiting precision CNS-targeted therapy. To synthesize recent evidence on...

DOI: 10.1017/s1092852926101187 Full text Major depressive disorder Treatment-resistant depression Cns biomarkers Intravenous ketamine +3

Changes in adipokine concentrations in antidepressant-resistant bipolar depression after ketamine infusion and electroconvulsive therapy

The World Journal of Biological Psychiatry July 4, 2022 Monika Dmitrzak-Weglarz, M. Tyszkiewicz-Nwafor, Filip Rybakowski et al.

Abstract Objectives This study attempts to assess the concentration of two opposite-acting adipokines (anti-inflammatory adiponectin and pro-inflammatory resistin) in antidepressant-resistant patients undergoing ketamine infusion (KI) and electroconvulsive therapy (ECT). Methods The study group comprised 52 patients hospitalised due to episodes of depression in the course of bipolar disorders....

DOI: 10.1080/15622975.2022.2097739